A new study published in the Journal of the American Academy of Orthopaedic Surgeons shows that patients with advanced osteoarthritis who undergo total joint replacement, significantly lower their risk of falls after surgery as compared to patients who opt out of surgery.
An analysis of more than 140 patients from a hospital in Italy suggests spinal fractures could help predict which patients were at an increased risk for negative outcomes with COVID-19.
An analysis of GoogleAnalytics data suggests use of FRAX fracture risk assessments declined by 58% globally in April 2020 compared to February 2020.
A study published in the New England Journal of Medicine earlier this year of patients with sciatica lasting longer than four months due to lumbar disk herniation, finds that microdiskectomy was superior to nonsurgical care in controlling pain six months post-op.
Researchers have created a machine-learning algorithm that can detect subtle signs of osteoarthritis—too abstract to register in the eye of a trained radiologist—on an MRI scan taken years before symptoms even begin.
An analysis of 22k prostate cancer patients over a 15-year period suggests less than 1-in-4 undergo bone mineral density testing after androgen deprivation therapy.
A year from now, with all the luck and scientific progress in the world, we’ll be free to roam again. There may be a whole raft of new stressors waiting for us, but the work you do now to help keep your patients mentally healthy will pay off in meaningful ways.
Numbers of a new type of cell discovered in the blood of rheumatoid arthritis patients increase dramatically immediately before a flare.
The underlying pathogenesis of rheumatoid arthritis with and without autoantibodies may be different. Researchers say that "it is time to formally subdivide RA into type 1 (with autoantibodies) and type 2 (without autoantibodies)."
In this week's news roundup from Rheumatology Network, we highlight this week's leading stories including two stories on new developments in osteoporosis treatment. In one, a physician-scientist describes "a crisis in the treatment of osteoporosis" due to severe side effects. Learn more about this story and others in this week's news roundup.
Patients taking nitrogen-containing bisphosphonates have a lower risk of developing and dying from pneumonia after hip fracture compared with patients taking other types of medication for osteoporosis or no drugs for osteoporosis at all, a study published in the Journal of Bone and Mineral Research has found.
Delays to denosumab injections increase the risk of vertebral fractures, a study published in the Annals of Internal Medicine has shown, highlighting the importance of trying to ensure that, while covid-19 is disrupting many medical services, the pandemic does not impact on the timing of denosumab injections.
Belimumab (Benlysta, GlaxoSmithKline) can improve the kidney health of people with lupus nephritis, a new phase 3 clinical trial suggests.
In women 50 years of age or older, the risk of atypical femur fracture increased with longer bisphosphonate use, Asian ancestry, shorter height, higher weight and glucocorticoid use for one year or more, but this risk rapidly decreased after bisphosphonate discontinuation, according to a study recently published in New England Journal of Medicine.
The assessed sickle cell population had high rates of low vitamin D levels and bone marrow density, but there was no strong correlation between both conditions.
Despite major advances in axial spondyloarthritis and an increasing number of therapeutic options, questions remain related to the optimized treatment strategies and to the individual drug choice, according to a review published in Current Rheumatology Reports.
Patients with fibromyalgia syndrome may present with elevated intramuscular pressure, which might represent a diagnostic aid in fibromyalgia syndrome and a target for treatment to reduce muscle pressure, according to a study recently published in The Journal of Rheumatology.
In patients with acute gout, cyclo-oxygenase-2 (COX-2) inhibitors, especially etoricoxib (Arcoxia, Merck & Co.), may result in a greater clinical response than traditional non-steroidal anti-inflammatory drugs (NSAIDs), according to a study published in BMJ Open.
In juvenile idiopathic arthritis, predictive genomic risk scores may enhance current diagnosis protocols, prioritizing higher-risk patients for follow-up and reducing treatment delays, according to a study published this month in Annals of Rheumatic Diseases.
An analysis of data from 4 decades offers insight into the impact of treatment advances and changes in risk factor management on incidence of hip fracture.
Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.
Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.
Golimumab (Simponi Aria, Janssen/J&J) has been approved by the U.S. Food and Drug Administration for two pediatric conditions:active pediatric juvenile idiopathic arthritis (JIA) and active pediatric psoriatic arthritis.
Preoperative knee extensor muscle strength training in patients with knee osteoarthritis may have no clinical effect on total knee arthroplasty (TKA), according to a systematic review published online this month in Osteoarthritis and Cartilage.
This approval makes the drug the first of its kind to treat polyarticular juvenile idiopathic arthritis and psoriatic arthritis in a pediatric population.
The U.S. Food and Drug Administration has approved tofacitinib Xeljanz, Pfizer) for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
Autologous hematopoietic stem cell transplants (AHSCT) improve the quality of life in patients with systemic sclerosis (SSc), researchers say.
Various drug therapies, including several cytokine blockers, are showing promise in addressing COVID-19 related cytokine storm syndrome, says Dr. Randall Cron of Children’s Hospital of Alabama.
Type I Interferon Inhibition Could Benefit Systemic Lupus Erythematosus
The approval of tocilizumab for giant cell arteritis as a glucocorticoid-sparing treatment is the most significant development in the management of this condition over the past four years, a review of the literature suggests.
